1 story in the last 7 days
The latest retatrutide news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks retatrutide across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

A single 79-year-old patient received early access to Eli Lilly's experimental obesity drug retatrutide through the FDA's compassionate use program. Stat News reported the patient may be President Donald Trump. The drug targets GIP, glucagon, and GLP-1 hormones. A Phase 3 trial showed 28 percent weight loss over 80 weeks.
Summaries by ByteBrief